TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9459253

Group type: EXPERIMENTAL
Intervention: Lidocaine 3 mL (2%)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Meperidine 40 mg
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Fentanyl 150 microg
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Morphine 4 mg
Number of subjects: 175

Group type: COMPARATOR
Intervention: Normal saline 3 mL (placebo)
Number of subjects: 175
Study: 7707111

Group type: EXPERIMENTAL
Intervention: Tamoxifen 10 mg orally, twice daily for 3 months
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 2496357

Group type: EXPERIMENTAL
Intervention: Aspirin-dipyridamole (990 mg/225 mg daily)
Number of subjects: 16
Study: 580589

Group type: EXPERIMENTAL
Intervention: meproscillarin (4 X 0.25 mg/d for 7 days)
Number of subjects: 11

Group type: COMPARATOR
Intervention: placebo (7 days)
Number of subjects: 11
Study: 31253207

Group type: EXPERIMENTAL
Intervention: Propofol target-controlled infusion at 1.5 times C0
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Propofol target-controlled infusion at 2 times C0
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Propofol target-controlled infusion at 2.5 times C0
Number of subjects: 180
Study: 29282073

Group type: EXPERIMENTAL
Intervention: Physical training, exercises, and pain education combined
Number of subjects: 164

Group type: COMPARATOR
Intervention: Pain education only
Number of subjects: 164
Study: 26721039

Group type: EXPERIMENTAL
Intervention: Interrupted sutures
Number of subjects: 138

Group type: COMPARATOR
Intervention: Continuous sutures
Number of subjects: 138
Study: 23374763

Group type: EXPERIMENTAL
Intervention: Hydrogen-rich water
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo water
Number of subjects: 30
Study: 21515482

Group type: EXPERIMENTAL
Intervention: Cisplatin and docetaxel (DC) regimen with concurrent radiotherapy
Number of subjects: 48

Group type: COMPARATOR
Intervention: Fluorouracil (PF) regimen with concurrent radiotherapy
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Cisplatin and docetaxel (DC) regimen
Number of subjects: 48

Group type: COMPARATOR
Intervention: Fluorouracil (PF) regimen
Number of subjects: 48
Study: 19456294

Group type: EXPERIMENTAL
Intervention: Hypocaloric low-fat diet
Number of subjects: 35

Group type: COMPARATOR
Intervention: Weight maintenance diet
Number of subjects: 35
Study: 16371610

Group type: EXPERIMENTAL
Intervention: Intranasal sufentanil 0.05 microg x kg(‐1) /puff
Number of subjects: 40

Group type: COMPARATOR
Intervention: Intranasal sufentanil 0.025 microg x kg(‐1) /puff
Number of subjects: 40
Study: 14986206

Group type: EXPERIMENTAL
Intervention: Intracorneal ring implantation
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (PKP without intracorneal ring)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 20
Study: 11091188

Group type: EXPERIMENTAL
Intervention: rhuIL-10 (8 microg/kg/d subcutaneously for 10 days)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 9307357

Group type: EXPERIMENTAL
Intervention: Unconditional confidentiality assurance
Number of subjects: 562

Group type: EXPERIMENTAL
Intervention: Conditional confidentiality assurance
Number of subjects: 562

Group type: COMPARATOR
Intervention: No confidentiality assurance
Number of subjects: 562
Study: 8317719

Group type: EXPERIMENTAL
Intervention: Intrathecal fentanyl infusion (0.5 mL saline bolus followed by 120 micrograms fentanyl infusion in 24 h)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Intrathecal morphine infusion (0.5 mL saline bolus followed by 200 micrograms morphine infusion in 24 h)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Intrathecal morphine bolus (200 micrograms morphine as a single bolus followed by 3 mL saline infusion in 24 h)
Number of subjects: 60
Study: 2895171

Group type: EXPERIMENTAL
Intervention: Beta-blockers/diuretics
Number of subjects: 4668

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4668
Study: 31570566

Group type: EXPERIMENTAL
Intervention: Telapristone acetate (TPA) 12 mg daily for 2 to 10 weeks
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Telapristone acetate (TPA) in premenopausal women
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Telapristone acetate (TPA) in subset of tumors with ≥30% Ki67 reduction
Number of subjects: 70
Study: 28084851

Group type: EXPERIMENTAL
Intervention: Ai Chi exercise group
Number of subjects: 40

Group type: COMPARATOR
Intervention: Land-based exercise control group
Number of subjects: 40
Study: 26858426

Group type: EXPERIMENTAL
Intervention: Sleep deprivation (participants who remained awake all night)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Rested participants (participants who slept all night in laboratory bedrooms)
Number of subjects: 0
Study: 25456710

Group type: EXPERIMENTAL
Intervention: Exercise training alone
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Ventilation alone
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Combined treatment (exercise training + ventilation)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 45
Study: 21890575

Group type: EXPERIMENTAL
Intervention: STN‐DBS implants
Number of subjects: 15
Study: 20167117

Group type: EXPERIMENTAL
Intervention: Allopurinol 500 mg IV
Number of subjects: 220

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 220
Study: 18056144

Group type: EXPERIMENTAL
Intervention: Immediate release methylphenidate (Ritalin), administered three times a day
Number of subjects: 21

Group type: COMPARATOR
Intervention: No medication (control)
Number of subjects: 21
Study: 16616020

Group type: EXPERIMENTAL
Intervention: Statin treatment within 96 hours of AMI onset
Number of subjects: 486

Group type: COMPARATOR
Intervention: No statin treatment
Number of subjects: 486

Group type: EXPERIMENTAL
Intervention: Statin treatment
Number of subjects: 486
Study: 12834362

Group type: EXPERIMENTAL
Intervention: Nifedipine gastrointestinal‐transport‐system (GITS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Co‐amilozide (hydrochlorothiazide and amiloride)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nifedipine GITS
Number of subjects: 0
Study: 11206101

Group type: EXPERIMENTAL
Intervention: Trimetazidine IV infusion started before PTCA and continued for 48 hours
Number of subjects: 94

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study: 8828680

Group type: EXPERIMENTAL
Intervention: Aerobic exercise training (AEX)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Weight loss (WL)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: AEX + WL
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control (Con)
Number of subjects: 47
Study: 1424426

Group type: EXPERIMENTAL
Intervention: Atropine (0.1 to 2.3 mg per subject)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 2867772

Group type: EXPERIMENTAL
Intervention: Alcuronium
Number of subjects: 80

Group type: COMPARATOR
Intervention: Tubocurarine
Number of subjects: 80

Group type: COMPARATOR
Intervention: Pancuronium
Number of subjects: 80

Group type: COMPARATOR
Intervention: Vecuronium
Number of subjects: 80
Study: 31631029

Group type: EXPERIMENTAL
Intervention: Positive Dix Hallpike/head-roll test for benign paroxysmal positional vertigo
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Cardiovascular medication use
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: High postural sway when standing on the floor with eyes closed (sway path ≥160 mm)
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Anxiety (Generalized Anxiety Disorder Scale 7-item Scale score ≥8)
Number of subjects: 305

Group type: COMPARATOR
Intervention: Age 70 years and over
Number of subjects: 305
Study: 29917190

Group type: EXPERIMENTAL
Intervention: Transhepatic arterial chemoembolization (TACE)
Number of subjects: 110
Study: 26833462

Group type: EXPERIMENTAL
Intervention: NNC0114‐0005 (0.0025‐25 mg/kg)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: NNC0114‐0005 (25 mg/kg)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: NNC0114‐0005
Number of subjects: 64
Study: 24762049

Group type: EXPERIMENTAL
Intervention: AF ablation in patients with a history of decompensated TIC who maintained sinus rhythm or had paroxysmal AF (group 1)
Number of subjects: 674

Group type: EXPERIMENTAL
Intervention: AF ablation in patients with a history of decompensated TIC who had persistent or longstanding persistent AF (group 2)
Number of subjects: 674

Group type: EXPERIMENTAL
Intervention: AF ablation in patients without TIC who had paroxysmal AF (group 3)
Number of subjects: 674

Group type: EXPERIMENTAL
Intervention: AF ablation in patients without TIC who had persistent or longstanding persistent AF (group 4)
Number of subjects: 674

Group type: COMPARATOR
Intervention: Heart rate control during AF without sinus conversion
Number of subjects: 674
Study: 23263427

Group type: EXPERIMENTAL
Intervention: Mouthrinse formulated from ethanol extract of Terminalia chebula
Number of subjects: 60
Study: 20975266

Group type: EXPERIMENTAL
Intervention: Intracoronary infusion of autologous CD34+ stem cells
Number of subjects: 112

Group type: COMPARATOR
Intervention: Intracoronary saline injections (placebo control)
Number of subjects: 112
Study: 18476420

Group type: EXPERIMENTAL
Intervention: Gengxueting (GXT) one capsule every day for 90 consecutive days before surgical operation
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group (surgery alone)
Number of subjects: 64
Study: 16247305

Group type: EXPERIMENTAL
Intervention: Computer-assisted fluoroscopic ORIF technique
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional fluoroscopic-assisted ORIF technique
Number of subjects: 30
Study: 12401046

Group type: EXPERIMENTAL
Intervention: Intraoral force applied from the canine region at a 30 degrees angle to the occlusal plane
Number of subjects: 20

Group type: COMPARATOR
Intervention: Extraoral force applied 20 mm above the maxillary occlusal plane
Number of subjects: 20
Study: 10024334

Group type: EXPERIMENTAL
Intervention: Irbesartan
Number of subjects: 188

Group type: COMPARATOR
Intervention: Amlodipine
Number of subjects: 188
Study: 7580006

Group type: EXPERIMENTAL
Intervention: Gonal‐F (225 IU/day, SC)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Metrodin (225 IU/day, IM)
Number of subjects: 20
Study: 2311334

Group type: COMPARATOR
Intervention: Transdermal nicotine patch
Number of subjects: 0
Study: 6778345

Group type: EXPERIMENTAL
Intervention: PCP-8 (octavalent vaccine) administered at 25 micrograms of each serotype at 3-6 months and again at 18-24 months.
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: PCP-7 or PCP-8 administered to 44 infants followed for two years.
Number of subjects: 71

Group type: COMPARATOR
Intervention: Saline placebo (control group).
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Natural infection or immunization.
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: PCP immunization.
Number of subjects: 71
Study: 31431077

Group type: EXPERIMENTAL
Intervention: Bidirectional, automated text messages prior to the procedure
Number of subjects: 71

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 71
Study: 28348190

Group type: EXPERIMENTAL
Intervention: Swallowing Intervention Package (SIP) delivered pre-treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard rehabilitation (control group)
Number of subjects: 0
Study: 26471791

Group type: EXPERIMENTAL
Intervention: Face-to-face, group-based intervention (six, theory-based two-hour sessions delivered over 8 weeks targeting healthy eating and physical activity)
Number of subjects: 174

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Face-to-face, group-based intervention
Number of subjects: 174
Study: 23421568

Group type: EXPERIMENTAL
Intervention: Aprepitant
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 20626736

Group type: EXPERIMENTAL
Intervention: Regular saline flushes of ECC
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Regional citrate anticoagulation (RCA)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: AN69 ST membrane after ECC priming
Number of subjects: 10
Study: 19806814

Group type: EXPERIMENTAL
Intervention: Topical application of aprotinin (500,000 KIU, 50 mL)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Normal saline (50 mL)
Number of subjects: 128
Study: 17052775

Group type: EXPERIMENTAL
Intervention: Folic acid 2.5 mg/day (group A)
Number of subjects: 137

Group type: COMPARATOR
Intervention: Control group (not treated with folic acid, group B)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Folic acid 2.5 mg/day (group A) in patients with MTHFR 677TT mutation
Number of subjects: 137
Study: 15030340

Group type: EXPERIMENTAL
Intervention: Bexarotene gel monotherapy
Number of subjects: 55
Study: 11601949

Group type: EXPERIMENTAL
Intervention: Pharmacotherapy for dementia, details on dosage and duration not available
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Assessment of medications and health conditions, details not available
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Early identification strategies, details not available
Number of subjects: 0
Study: 9484373

Group type: EXPERIMENTAL
Intervention: Riboflavin (400 mg)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 8045623

Group type: EXPERIMENTAL
Intervention: Deworming drugs
Number of subjects: 200

Group type: COMPARATOR
Intervention: Traditional therapies
Number of subjects: 200
Study: 2839729

Group type: EXPERIMENTAL
Intervention: Tight control (tc) with normal mean HbA1 levels < 8.6% (n = 50)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Poor control (pc) with abnormal mean HbA1 levels ≥ 8.6% (n = 33)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Well-controlled patients with initially abnormal peripheral nerve tests
Number of subjects: 83

Group type: COMPARATOR
Intervention: Well-controlled patients with normal nerve tests at baseline
Number of subjects: 83
Study: 31564582

Group type: EXPERIMENTAL
Intervention: BASIL model in JUVENTAS cohort
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PREVENT III model in JUVENTAS cohort
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BASIL model in JUVENTAS population
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: FINNVASC model in PADI population
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All models in each population
Number of subjects: 0
Study: 30096354

Group type: EXPERIMENTAL
Intervention: Intravitreous ranibizumab (0.5 mg)
Number of subjects: 305
Study: 28314813

Group type: EXPERIMENTAL
Intervention: Anodal tDCS (atDCS)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Sham tDCS (stDCS)
Number of subjects: 48
Study: 25991654

Group type: EXPERIMENTAL
Intervention: Mirtazapine
Number of subjects: 1582

Group type: EXPERIMENTAL
Intervention: Mianserin
Number of subjects: 1582

Group type: EXPERIMENTAL
Intervention: Trazodone
Number of subjects: 1582

Group type: EXPERIMENTAL
Intervention: Nefazodone
Number of subjects: 1582

Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 1582

Group type: EXPERIMENTAL
Intervention: Duloxetine
Number of subjects: 1582

Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitors
Number of subjects: 1582
Study: 23072926

Group type: EXPERIMENTAL
Intervention: Oral unsaturated fat load test (OFLT)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control (healthy subjects)
Number of subjects: 32
Study: 21501131

Group type: EXPERIMENTAL
Intervention: Pressure-controlled ventilation
Number of subjects: 42

Group type: COMPARATOR
Intervention: Volume-controlled ventilation
Number of subjects: 42
Study: 19435154

Group type: EXPERIMENTAL
Intervention: Motor coordination training for 20 minutes daily over 3 weeks
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Motor coordination training for children with balance problems
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control group (received training after posttest)
Number of subjects: 53
Study: 16938683

Group type: EXPERIMENTAL
Intervention: Self-management group intervention based on the Self-Management of Well-being (SMW) theory
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 100
Study: 15511345

Group type: EXPERIMENTAL
Intervention: Positioning catheter tip in central area of the endometrial cavity (relative position analysis)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Positioning catheter tip in absolute positions (absolute position analysis)
Number of subjects: 400
Study: 11477728

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) 1 mg
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 9554816

Group type: EXPERIMENTAL
Intervention: Enalapril (10 mg/day for >1 year)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 7810179

Group type: EXPERIMENTAL
Intervention: Zinc supplementation
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Cereal diet
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control group (without zinc supplementation)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control group (without cereal diet)
Number of subjects: 51
Study: 3122335

Group type: COMPARATOR
Intervention: Standard amino acid solutions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BCAA enriched solutions
Number of subjects: 0
Study: 29294910

Group type: EXPERIMENTAL
Intervention: Controlling behavior by a romantic partner
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Feelings of passionate love
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Baseline reports of at least one form of ARA
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gender (female respondents)
Number of subjects: 0
Study: 30316341

Group type: EXPERIMENTAL
Intervention: Living kidney related donations (LKRD)
Number of subjects: 2683
Study: 27152523

Group type: EXPERIMENTAL
Intervention: Aerobic exercise (4x/week for 4 weeks)
Number of subjects: 57

Group type: COMPARATOR
Intervention: No activity (control group)
Number of subjects: 57
Study: 26435241

Group type: EXPERIMENTAL
Intervention: Mepilex Border®
Number of subjects: 111

Group type: COMPARATOR
Intervention: Zetuvit® with Cosmopor E®
Number of subjects: 111

Group type: COMPARATOR
Intervention: Zetuvit® with Opsite Post‐Op Visible®
Number of subjects: 111

Group type: COMPARATOR
Intervention: Aquacel Surgical®
Number of subjects: 111

Group type: COMPARATOR
Intervention: Standard dressing
Number of subjects: 111
Study: 24021518

Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study: 20970825

Group type: EXPERIMENTAL
Intervention: Periprostatic lignocaine injection
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Spinal saddle block
Number of subjects: 75

Group type: COMPARATOR
Intervention: No anesthesia (Group 1)
Number of subjects: 75
Study: 19086193

Group type: EXPERIMENTAL
Intervention: Firm foam
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Medium foam
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Soft foam
Number of subjects: 32

Group type: COMPARATOR
Intervention: Solid surface
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Vision (eyes open vs closed)
Number of subjects: 32
Study: 12382382

Group type: EXPERIMENTAL
Intervention: Plasma ball device
Number of subjects: 42

Group type: COMPARATOR
Intervention: Standard eye fixation induction control condition
Number of subjects: 42
Study: 9593458

Group type: EXPERIMENTAL
Intervention: Foscarnet, 50 mg three times per day administered intravenously for 4 weeks
Number of subjects: 10
Study: 7642328

Group type: EXPERIMENTAL
Intervention: Large e-PTFE membranes (Gortex) placed to cover the lesions
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control sites (no membranes used)
Number of subjects: 20
Study: 2664628

Group type: EXPERIMENTAL
Intervention: 0.5% levobunolol
Number of subjects: 391

Group type: EXPERIMENTAL
Intervention: 1% levobunolol
Number of subjects: 391

Group type: COMPARATOR
Intervention: 0.5% timolol
Number of subjects: 391

Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 391
Study: 360495

Group type: EXPERIMENTAL
Intervention: Intravenous infusions of 10% glycerol in 0.9% NaCl‐‐5% glucose solutions administered twice daily for 6 days to 26 patients
Number of subjects: 51

Group type: COMPARATOR
Intervention: NaCl‐‐glucose solutions administered to 25 controls
Number of subjects: 51
Study: 30916203

Group type: EXPERIMENTAL
Intervention: Treatment of hypertension
Number of subjects: 912

Group type: EXPERIMENTAL
Intervention: Control of hypertension
Number of subjects: 912

Group type: EXPERIMENTAL
Intervention: Prevalence of arterial hypertension
Number of subjects: 912
Study: 28361275

Group type: EXPERIMENTAL
Intervention: Lumbar spinal stabilization exercise program (3 days a week for 8 weeks)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Lumbar spinal stabilization exercise program
Number of subjects: 38
Study: 25413168

Group type: EXPERIMENTAL
Intervention: Cognitive‐behavioural training programme for pain management (6 weekly group sessions supervised by a psychologist and a physiotherapist)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Ordinary GP care (control group)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Cognitive‐behavioural training programme for pain management
Number of subjects: 111
Study: 23331443

Group type: EXPERIMENTAL
Intervention: ramipril 2.5 mg daily
Number of subjects: 60

Group type: COMPARATOR
Intervention: no treatment
Number of subjects: 60
Study: 21273355

Group type: EXPERIMENTAL
Intervention: Prolonged carotid sinus reflex (CSR) after CAS
Number of subjects: 80

Group type: COMPARATOR
Intervention: No prolonged CSR
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Delayed renal impairment
Number of subjects: 80
Study: 19671411

Group type: EXPERIMENTAL
Intervention: Oxymatrine Capsule, 0.4 g once a day for 3 months
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no oxymatrine)
Number of subjects: 60
Study: 17094673

Group type: EXPERIMENTAL
Intervention: 0.75 mg alprazolam
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 1.75 mg alprazolam
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18